| scholarly article | Q13442814 |
| P50 | author | Ron Shapiro | Q59747328 |
| P2093 | author name string | James B Young | |
| James F Trotter | |||
| Edgar L Milford | |||
| Alan B Leichtman | |||
| Rami T Bustami | |||
| P2860 | cites work | Chronic renal failure after transplantation of a nonrenal organ | Q28204928 |
| Controversies in the management of hepatitis C virus infection after liver transplantation. | Q35572035 | ||
| Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1 | Q43513598 | ||
| Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). | Q43575684 | ||
| Rapamycin: friend, foe, or misunderstood? | Q44436728 | ||
| Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up | Q44463528 | ||
| Steroid-free liver transplantation in children | Q44707729 | ||
| P433 | issue | 4 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 874-886 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Immunosuppression: evolution in practice and trends, 1993-2003. | |
| P478 | volume | 5 |
| Q46812809 | A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years |
| Q34511576 | Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice. |
| Q30450405 | Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation |
| Q50490977 | Azathioprine-associated pure red cell aplasia in renal transplant recipients: a report of two cases. |
| Q36611514 | Combination of double negative T cells and anti-thymocyte serum reverses type 1 diabetes in NOD mice |
| Q45121876 | Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation |
| Q37916814 | Controversies about induction therapy |
| Q57791920 | Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans |
| Q30431515 | Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry |
| Q51501476 | Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. |
| Q37423540 | Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. |
| Q36662474 | Drug insight: maintenance immunosuppression in kidney transplant recipients |
| Q37960177 | Emerging drugs for the treatment of transplant rejection |
| Q42963475 | Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. |
| Q26783981 | Everolimus in de novo liver transplant recipients: a systematic review |
| Q38696621 | Food allergies developing after solid organ transplant |
| Q33779071 | Graft Function and Intermediate-Term Outcomes of Kidney Transplants Improved in the Last Decade: Analysis of the United States Kidney Transplant Database |
| Q36447876 | Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients |
| Q33577374 | Human allograft rejection in humanized mice: a historical perspective |
| Q53782053 | IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. |
| Q37227882 | Immunosuppression in renal transplantation: some aspects for the modern era. |
| Q36448818 | Immunosuppression: evolution in practice and trends, 1994-2004. |
| Q36601332 | Immunosuppressive therapy protocols in kidney transplantation in adults |
| Q42910495 | Introduction of Mycophenolate Mofetil in Maintenance Liver Transplant Recipients: What Can We Expect? Results of a 10-Year Experience |
| Q37332700 | Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors? |
| Q34140362 | Long-term linear growth and puberty in pediatric liver transplant recipients |
| Q46356692 | Maintenance immunosuppressive therapy in adult renal transplantation: a single center analysis. |
| Q36528984 | Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity |
| Q46387298 | Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. |
| Q81366398 | Monitoring T cell alloreactivity after organ transplantation |
| Q79144706 | Mycophenolate mofetil versus sirolimus as an adjunct to calcineurin inhibition after renal transplantation |
| Q37274049 | Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation |
| Q37305589 | Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii |
| Q46717317 | Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks |
| Q35611179 | Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction |
| Q38456262 | Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update |
| Q35615865 | Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice |
| Q38187176 | Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy |
| Q28080994 | Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes |
| Q40385827 | Renal transplantation: the present and the future |
| Q42601070 | Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis |
| Q55266341 | Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network. |
| Q51034908 | Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR. |
| Q36847294 | Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma |
| Q38239572 | Steroid withdrawal in kidney allograft recipients |
| Q40313782 | Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored. |
| Q41488787 | Tacrolimus and mycophenolate mofetil associations: Induction of oxidative stress or antioxidant effect? |
| Q40265150 | The appropriate dose of thymoglobulin induction therapy in kidney transplantation. |
| Q43061565 | The different effects of cyclosporin A and rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction |
| Q37176386 | The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation |
| Q46136869 | The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients |
| Q36675465 | The role of basiliximab induction therapy in organ transplantation |
| Q33388015 | Thymoglobulin--new approaches to optimal outcomes. |
| Q48736881 | Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database |
| Q38165842 | Trends in the biosynthesis and production of the immunosuppressant tacrolimus (FK506). |
| Q40073855 | Trends in the use of maintenance immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-based study |
Search more.